Functional magnetic resonance imaging of BDNF val66met polymorphism in unmedicated subjects at high genetic risk of schizophrenia performing a verbal memory task

Psychiatry Research - Neuroimaging

Volumn 183, Issue 3, 2010, Pages 195-201

  Baig, Benjamin J ^a   Whalley, Heather C ^a   Hall, Jeremy ^a   McIntosh, Andrew M ^a   Job, Dominic E ^a   Cunningham Owens, David G ^a   Johnstone, Eve C ^a   Lawrie, Stephen M ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

BDNF; Cingulate; FMRI; Prefrontal; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAMIDE PEROXIDE; METHIONINE; PEROXIDE; UREA; VALINE;

ADULT; ARTICLE; BEHAVIOR; BRAIN REGION; CINGULATE GYRUS; DNA POLYMORPHISM; ELECTROENCEPHALOGRAM; EPISODIC MEMORY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC RISK; GENOTYPE; HOMOZYGOTE; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MALE; OCCIPITAL CORTEX; PARIETAL LOBE; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; TASK PERFORMANCE; VERBAL MEMORY; ANALOGS AND DERIVATIVES; BLOOD; BRAIN CORTEX; BRAIN MAPPING; COMPLICATION; GENETIC POLYMORPHISM; GENETICS; IMAGE PROCESSING; LEARNING; MEMORY DISORDERS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PSYCHOLOGY; VASCULARIZATION;

BRAIN MAPPING; BRAIN-DERIVED NEUROTROPHIC FACTOR; CEREBRAL CORTEX; GENOTYPE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MEMORY DISORDERS; METHIONINE; PEROXIDES; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; UREA; VALINE; VERBAL LEARNING;

EID: 77956170557     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2010.06.009     Document Type: Article

References (77)

1. Aguilera M., Arias B., Wichers M., Barrantes-Vidal N., Moya J., Villa H., Van Os J., Ibanez M.I., Ruiperez M.A., Ortet G., Fañanás L. Early adversity and 5-HTT/BDNF genes: new evidence of gene-environment interactions on depressive symptoms in a general population. Psychological Medicine 2009, 39:1425-1432.
2. Alleva E., Francia N. Psychiatric vulnerability: suggestions from animal models and role of neurotrophins. Neuroscience and Biobehavioral Reviews 2009, 33(4):525-536.
3. Angelucci F., Aloe L., Iannitelli A., Gruber S.H., Mathe A.A. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. European Neuropsychopharmacology 2005, 15(3):311-317.
4. Bath K.G., Lee F.S. Variant BDNF (Val66Met) impact on brain structure and function. Cognitive, Affective & Behavioral Neuroscience 2006, 6(1):79-85.
5. Bekinschtein P., Cammarota M., Katche C., Slipczuk L., Rossato J.I., Goldin A., Izquierdo I., Medina J.H. BDNF is essential to promote persistence of long-term memory storage. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(7):2711-2716.
6. Buckley P.F., Pillai A., Evans D., Stirewalt E., Mahadik S. Brain derived neurotropic factor in first-episode psychosis. Schizophrenia Research 2007, 91(1-3):1-5.
7. Chen Z.Y., Patel P.D., Gayatree S., Meng C.X., Teng K., Hempstead B.L., Lee F.S. Variant brain-derived neurotrophic factor (BDNF) (Met 66) alters the intracellular trafficking and actvity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. Journal of Neuroscience 2004, 24(18):4401-4411.
8. Connor B., Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Research - Brain Research Reviews 1998, 27(1):1-39.
9. Curtis V.A., Bullmore E.T., Brammer M.J., Wright I.C., Williams S.C., Morris R.G., Sharma T.S., Murray R.M., McGuire P.K. Attenuated frontal activation during a verbal fluency task in patients with schizophrenia. American Journal of Psychiatry 1998, 155(8):1056-1063.
10. Djalali S., Holtje M., Grosse G., Rothe T., Stroh T., Grosse J., Deng D.R., Hellweg R., Grantyn R., Hortnagl H., Ahnert-Hilger G. Effects of brain-derived neurotrophic factor (BDNF) on glial cells and serotonergic neurones during development. Journal of Neurochemistry 2005, 92(3):616-627.
11. Duncan J., Owen A.M. Common regions of the human frontal lobe recruited by diverse cognitive demands. Trends in Neurosciences 2000, 23(10):475-483.
12. Duncan L.E., Hutchison K.E., Carey G., Craighead W.E. Variation in brain-derived neurotrophic factor (BDNF) gene is associated with symptoms of depression. Journal of Affective Disorders 2009, 115(1-2):215-219.
13. Durany N., Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. European Psychiatry 2004, 19:326-337.
14. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., Weinberger D.R. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112(2):257-269. [see comment].
15. Eker C., Kitis O., Ozan E., Okur H., Eker O.D., Ersoy M.A., Akdeniz F., Vahip S., Akarsu N., Gonul A.S. BDNF gene Val66Met polymorphism associated grey matter changes in human brain. Bulletin of Clinical Psychopharmacology 2005, 15(3):104-111.
16. Gallinat J., Schubert F., Bruhl R., Hellweg R., Klar A.A., Kehrer C., Wirth C., Sander T., Lang U.E. Met carriers of BDNF Val66Met genotype show increased N-acetylaspartate concentration in the anterior cingulate cortex. Neuroimage 2010, 49:767-771.
17. Gama C.S., Andreazza A.C., Kunz M., Berk M., Belmonte-de-Abreu P.S., Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neuroscience Letters 2007, 420(1):45-48.
18. Grillo R.W., Ottoni G.L., Leke R., Souza D.O., Portela L.V., Lara D.R. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. Journal of Psychiatric Research 2007, 41(1-2):31-35.
19. Guillin O., Demily C., Thibaut F. Brain-Derived Neurotrophic Factor in schizophrenia and its relation with dopamine. International Review of Neurobiology 2007, 78:377-395.
20. Hariri A.R., Goldberg T.E., Mattay V.S., Kolachana B.S., Callicott J.H., Egan M.F., Weinberger D.R. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. Journal of Neuroscience 2003, 23(17):6690-6694.
21. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999, 122(Pt 4):593-624.
22. Hashimoto T., Bergen S.E., Nguyen Q.L., Xu B., Monteggia L.M., Pierri J.N., Sun Z., Sampson A.R., Lewis D.A. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. Journal of Neuroscience 2005, 25(2):372-383.
23. Haznedar M.M., Buchsbaum M.S., Hazlett E.A., Shihabuddin L., New A., Siever L.J. Cingulate gyrus volume and metabolism in the schizophrenia spectrum. Schizophrenia Research 2004, 71(2-3):249-262.
24. Henseler I., Falkai P., Gruber O. A systematic fMRI investigation of the brain systems subserving different working memory components in schizophrenia. European Journal of Neuroscience 2009, 30(4):693-702.
25. Ho B.C., Andreasen N.C., Dawson J.D., Wassink T.H. Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. American Journal of Psychiatry 2007, 164(12):1890-1899.
26. Hodges A., Byrne M., Grant E., Johnstone E. People at risk of schizophrenia. Sample characteristics of the first 100 cases in the Edinburgh High-Risk Study. British Journal of Psychiatry 1999, 174:547-553. [see comment].
27. Huang T.L., Lee C.T. Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. Journal of Psychiatric Research 2006, 40(7):664-668.
28. Ikeda Y., Yahata N., Ito I., Nagano M., Toyota T., Yoshikawa T., Okubo Y., Suzuki H. Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. Schizophrenia Research 2008, 101(1-3):58-66.
29. Job D.E., Whalley H.C., McConnell S., Glabus M., Johnstone E.C., Lawrie S.M. Voxel-based morphometry of grey matter densities in subjects at high risk of schizophrenia. Schizophrenia Research 2003, 64(1):1-13.
30. Johnstone E.C., Abukmeil S.S., Byrne M., Clafferty R., Grant E., Hodges A., Lawrie S.M., Owens D.G. Edinburgh high risk study-findings after four years: demographic, attainment and psychopathological issues. Schizophrenia Research 2000, 46(1):1-15.
31. Kanazawa T., Glatt S.J., Kia-Keating B., Yoneda H., Tsuang M.T. Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder. Psychiatric Genetics 2007, 17(3):165-170.
32. Kawashima K., Ikeda M., Kishi T., Kitajima T., Yamanouchi Y., Kinoshita Y., Okochi T., Aleksic B., Tomita M., Okada T., Kunugi H., Inada T., Ozaki N., Iwata N. BDNF is not associated with schizophrenia: data from a Japanese population study and meta-analysis. Schizophrenia Research 2009, 112(1-3):72-79.
33. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13(2):261-276.
34. Knable M.B., Barci B.M., Webster M.J., Meador-Woodruff J., Torrey E.F., Stanley Neuropathology C. Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. Molecular Psychiatry 2004, 9(6):609-620.
35. Lang U.E., Hellweg R., Kalus P., Bajbouj M., Lenzen K.P., Sander T., Kunz D., Gallinat J. Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology 2005, 180(1):95-99.
36. Lencz T., Lipsky R.H., DeRosse P., Burdick K.E., Kane J.M., Malhotra A.K. Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. British Journal of Psychiatry 2009, 194:313-318.
37. Lessmann V. Neurotrophin-dependent modulation of glutamatergic synaptic transmission in the mammalian CNS. General Pharmacology 1998, 31(5):667-674.
38. Lipska B.K., Khaing Z.Z., Weickert C.S., Weinberger D.R. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. European Journal of Neuroscience 2001, 14(1):135-144.
39. Lipsky R.H., Marini A.M. Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Annals of the New York Academy of Sciences 2007, 1122:130-143.
40. MacDonald A.W., Thermenos H.W., Barch D.M., Seidman L.J. Imaging genetic liability to schizophrenia: systematic review of FMRI studies of patients' nonpsychotic relatives. Schizophrenia Bulletin 2009, 35(6):1142-1162.
41. Maldjian J.A., Laurienti P.J., Kraft R.A., Burdette J.H. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003, 19(3):1233-1239.
42. Matsuo K., Walss-Bass C., Nery F.G., Nicoletti M.A., Hatch J.P., Frey B.N., Monkul E.S., Zunta-Soares G.B., Bowden C.L., Escamilla M.A., Soares J.C. Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder. Neuropsychopharmacology 2009, 34(8):1904-1913.
43. Mesulam M.M. From sensation to cognition. Brain 1998, 121(Pt 6):1013-1052.
44. Meyer-Lindenberg A., Straub R.E., Lipska B.K., Verchinski B.A., Goldberg T., Callicott J.H., Egan M.F., Huffaker S.S., Mattay V.S., Kolachana B., Kleinman J.E., Weinberger D.R. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. Journal of Clinical Investigation 2007, 117(3):672-682.
45. Muller D.J., de Luca V., Sicard T., King N., Strauss J., Kennedy J.L. Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder: family-based association study. British Journal of Psychiatry 2006, 189:317-323.
46. Nemoto K., Ohnishi T., Mori T., Moriguchi Y., Hashimoto R., Asada T., Kunugi H. The Val66Met polymorphism of the brain-derived neurotrophic factor gene affects age-related brain morphology. Neuroscience Letters 2006, 397(1-2):25-29.
47. Neves-Pereira M., Cheung J.K., Pasdar A., Zhang F., Breen G., Yates P., Sinclair M., Crombie C., Walker N., St Clair D.M. BDNF gene is a risk factor for schizophrenia in a Scottish population. Molecular Psychiatry 2005, 10(2):208-212.
48. Palomino A., Vallejo-Illarramendi A., Gonzalez-Pinto A., Aldama A., Gonzalez-Gomez C., Mosquera F., Gonzalez-Garcia G., Matute C. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophrenia Research 2006, 86(1-3):321-322.
49. Paulus M.P., Hozack N.E., Zauscher B.E., Frank L., Brown G.G., McDowell J., Braff D.L. Parietal dysfunction is associated with increased outcome-related decision-making in schizophrenia patients. Biological Psychiatry 2002, 51(12):995-1004.
50. Paus T., Petrides M., Evans A.C., Meyer E. Role of the human anterior cingulate cortex in the control of oculomotor, manual, and speech responses: a positron emission tomography study. Journal of Neurophysiology 1993, 70(2):453-469.
51. Petryshen T.L., Sabeti P.C., Aldinger K.A., Fry B., Fran J.B., Schaffner S.F., Waggoner S.G., Tahl A.R., Sklar P. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Molecular Psychiatry 2009, 1-6.
52. Pezawas L., Verchinski B.A., Mattay V.S., Callicott J.H., Kolachana B.S., Straub R.E., Egan M.F., Meyer-Lindenberg A., Weinberger D.R. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. Journal of Neuroscience 2004, 24(45):10099-10102.
53. Pezawas L., Meyer-Lindenberg A., Goldman A.L., Verchinski B.A., Chen G., Kolachana B.S., Egan M.F., Mattay V.S., Hariri A.R., Weinberger D.R. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Molecular Psychiatry 2008, 13(7):709-716.
54. Pirildar S., Gonul A.S., Taneli F., Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004, 28(4):709-713.
55. Qian L., Zhao J., Shi Y., Zhao X., Feng G., Xu F., Zhu S., He L. Brain-derived neurotrophic factor and risk of schizophrenia: an association study and meta-analysis. Biochemical & Biophysical Research Communications 2007, 353(3):738-743.
56. Rosa A., Cuesta M.J., Fatjo-Vilas M., Peralta V., Zarzuela A., Fananas L. The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with risk for psychosis: evidence from a family-based association study. American Journal of Medical Genetics Part B, Neuropsychiatric Genetics: the Official Publication of the International Society of Psychiatric Genetics 2006, 141B(2):135-138.
57. Rybakowski J.K., Borkowska A., Czerski P.M., Skibinska M., Hauser J. Polymorphism of the brain-derived neurotrophic factor gene and performance on a cognitive prefrontal test in bipolar patients. Bipolar Disorders 2003, 5(6):468-472.
58. Rybakowski J.K., Borkowska A., Skibinska M., Szczepankiewicz A., Kapelski P., Leszczynska-Rodziewicz A., Czerski P.M., Hauser J. Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene. Psychiatry & Clinical Neurosciences 2006, 60(1):70-76.
59. Schumacher J., Jamra R.A., Becker T., Ohlraun S., Klopp N., Binder E.B., Schulze T.G., Deschner M., Schmal C., Hofels S., Zobel A., Illig T., Propping P., Holsboer F., Rietschel M., Nöthen M.M., Cichon S. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biological Psychiatry 2005, 58(4):307-314.
60. Shimizu E., Hashimoto K., Watanabe H., Komatsu N., Okamura N., Koike K., Shinoda N., Nakazato M., Kumakiri C., Okada S., Iyo M. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neuroscience Letters 2003, 351(2):111-114.
61. Sklar P., Gabriel S.B., McInnis M.G., Bennett P., Lim Y.M., Tsan G., Schaffner S., Kirov G., Jones I., Owen M., Craddock N., DePaulo J.R., Lander E.S. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Molecular Psychiatry 2002, 7(6):579-593. [see comment].
62. Szeszko P.R., Lipsky R., Mentschel C., Robinson D., Gunduz-Bruce H., Sevy S., Ashtari M., Napolitano B., Bilder R.M., Kane J.M., et al. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Molecular Psychiatry 2005, 10(7):631-636.
63. Takahashi M., Shirakawa O., Toyooka K., Kitamura N., Hashimoto T., Maeda K., Koizumi S., Wakabayashi K., Takahashi H., Someya T., Nawa H. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Molecular Psychiatry 2000, 5(3):293-300.
64. Tan Y.L., Zhou D.F., Cao L.Y., Zou Y.Z., Wu G.Y., Zhang X.Y. Effect of BDNF Val66Met genotype on episodic memory in schizophrenia. Schizophrenia Research 2005, 77(2-3):355-356.
65. Thome J., Foley P., Riederer P. Neurotrophic factors and the maldevelopment hypothesis of schizophrenic psychoses. Journal of Neural Transmission 1998, 105:85-100.
66. Toro, R, Chupin, M, Garnero, L, Leonard, G, Perron, M, Pike, B, Pitot, A, Richer, L, Veillette, S, Pausova, Z and others. 2009. Brain volumes and Val66Met polymorphism of the BDNF gene: local or global effects?. Brain structure and function. 213 (6), 501-509. [Erratum in Brain Structure & Function 2009, 214 (1), 87.].
67. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Research 2002, 110(3):249-257.
68. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002, 15(1):273-289.
69. Varnas K., Lawyer G., Jonsson E.G., Kulle B., Nesvag R., Hall H., Terenius L., Agartz I. Brain-derived neurotrophic factor polymorphisms and frontal cortex morphology in schizophrenia. Psychiatric Genetics 2008, 18(4):177-183.
70. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Molecular Psychiatry 2003, 8(6):592-610.
71. Whalley H.C., Simonotto E., Flett S., Marshall I., Ebmeier K.P., Owens D.G., Goddard N.H., Johnstone E.C., Lawrie S.M. fMRI correlates of state and trait effects in subjects at genetically enhanced risk of schizophrenia. Brain 2004, 127(Pt 3):478-490. [see comment].
72. Whalley H.C., Simonotto E., Marshall I., Owens D.G., Goddard N.H., Johnstone E.C., Lawrie S.M. Functional disconnectivity in subjects at high genetic risk of schizophrenia. Brain 2005, 128(Pt 9):2097-2108.
73. Whalley H.C., Simonotto E., Moorhead W., McIntosh A., Marshall I., Ebmeier K.P., Owens D.G., Goddard N.H., Johnstone E.C., Lawrie S.M. Functional imaging as a predictor of schizophrenia. Biological Psychiatry 2006, 60(5):454-462.
74. Whalley H.C., Gountouna V.E., Hall J., McIntosh A.M., Whyte M.C., Simonotto E., Job D.E., Owens D.C., Johnstone E.C., Lawrie S.M. Correlations between fMRI activation and individual psychotic symptoms in un-medicated subjects at high genetic risk of schizophrenia. BMC Psychiatry 2007, 7:61.
75. Whyte M.C., Whalley H.C., Simonotto E., Flett S., Shillcock R., Marshall I., Goddard N.H., Johnstone E.C., Lawrie S.M. Event-related fMRI of word classification and successful word recognition in subjects at genetically enhanced risk of schizophrenia. Psychological Medicine 2006, 36(10):1427-1439.
76. Wing J.K., Cooper J.E., Sartorius N. The Description and Classification of Psychiatric Symptoms. An Instruction Manual for the PSE and Catego Systems 1974, Cambridge University Press, Cambridge.
77. Yan Q., Rosenfeld R.D., Matheson C.R., Hawkins N., Lopez O.T., Bennett L., Welcher A.A. Expression of brain-derived neurotrophic factor protein in the adult rat central nervous system. Neuroscience 1997, 78(2):431-448.